Advertisement


Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer

2019 San Antonio Breast Cancer Symposium

Advertisement

Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast cancer in women who discontinued endocrine therapy at 5 years is likely to be about a third lower now than in his group’s previous report (Abstract GS2-04).



Related Videos

Breast Cancer

Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide

Nadine M. Tung, MD, of Beth Israel Deaconess Medical Center, discusses cisplatin vs doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment in BRCA-mutation carri...

Breast Cancer
Genomics/Genetics

Nicholas C. Turner, MD, PhD, on ctDNA Testing to Direct Targeted Therapies in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings from the plasmaMATCH trial, which showed that circulating tumor DNA testing offers ...

Breast Cancer
Immunotherapy

Ralph R. Weichselbaum, MD, on Oligometastatic Cancer: The Role of Radioimmunotherapy

Ralph R. Weichselbaum, MD, of the University of Chicago, summarizes a plenary lecture in which he presented data that could guide future clinical strategies: studies supporti...

Breast Cancer

Ian E. Krop, MD, PhD, on Trastuzumab Deruxtecan for Patients With Previously Treated, HER2-Positive Metastatic Breast Cancer

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses phase II trial findings on trastuzumab deruxtecan, a HER2-targeting antibody-drug conjugate, in patients with...

Breast Cancer

Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy

Joerg Heil, MD, PhD, of the University Hospital Heidelberg, discusses findings on how accurately this technique can diagnose residual disease and pathologic complete response...

Advertisement

Advertisement



Advertisement